|
Alzheimer's disease, a neurological disorder characterised with progressive cognitive decline, including memory loss, affects up to 5.8 million Americans today. Protein aggregates, made up of beta-amyloid or other proteins, occur in the brains of Alzheimer's patients. These beta-amyloid plaques appear to be a major cause of the disease. Scientists at St. Jude Children's Research Hospital discovered a subpopulation of immune cells that appear to inhibit the creation of beta-amyloid plaques, as well as the critical proteins involved in the process.
The findings of the study were published today inNature Immunology. People typically think of the immune system as being involved in defense from bacterial or viral infection, though there is growing interest in the role of the immune system in neurodegenerative diseases, said co-first author Jordy Saravia, Ph.D., St. JudeDepartment of Immunology. We uncovered an important immune cell communication axis that is protective in an Alzheimers disease model. Microglia are immunological cells in the brain that are responsible for the removal of beta-amyloid plaques. Microglia may lose their ability to clear these plaques as Alzheimer's disease progresses, instead producing inflammatory mediators that may increase beta-amyloid plaque formation. The St. Jude researchers discovered that increasing another type of immune cell called CD8+ T cells is critical for slowing this process by interacting with microglia. In turn, this connection proved critical for limiting beta-amyloid accumulation and preserving cognitive capacities in a mouse model of the disease. Our paper is the first to demonstrate that a subpopulation of CD8+T cells can be protective in a mouse model of Alzheimers disease, said co-first author Wei Su, Ph.D., St. Jude Department of Immunology. Moving forward, we may be able to extend this work to find an effective intervention for neurodegenerative diseases. Previous research has established complex roles for T cells and other immune system cells in Alzheimers disease. In particular, research groups using other experimental systems have suggested that certain T cells with inflammatory functions worsen the disease. However, the St. Jude scientists showed that CD8+T cells with suppressive features accumulate in the brains of both mouse models and patients with Alzheimers disease, highlighting that T cells play a complex role in this disease. We showed that CD8+T cells can play a protective role against Alzheimers disease pathogenesis, although there is also evidence for a contributing role, said corresponding authorHongbo Chi, Ph.D., St. Jude Department of Immunology. Our results demonstrate the need to better understand these complex neuro-immune interactions to improve outcomes for this neurodegenerative disease. To understand how T cells were delaying symptom progression in their Alzheimers disease model, the St. Jude group searched for the most abundant molecular interaction between CD8+T cells and the microglia. They found a protein on the surface of CD8+T cells, CXCR6, interacts with the protein CXCL16 expressed by microglia. The two surface proteins, CXCR6 and CXCL16, essentially performed a handshake between the two cells, communicating in both directions. Just like the firmness of a human handshake can convey information, so can the interaction of these two proteins on the outside of their respective cells. We found CD8+T cells use CXCR6 to interact with CXCL16 from microglia, Chi said. Moreover, CD8+T-cell accumulation, localization and function in the brain are regulated by CXCR6. The scientists determined how the handshake occurs and delays the onset of Alzheimers disease-related pathologies. The CD8+T cells first move next to the microglia, which are localized next to the beta-amyloid plaques. Then, the CD8+T cells use the handshake to signal to the microglia to stop causing uncontrolled inflammation, which, in turn, slows plaque growth and symptoms in the mouse models. When the scientists deleted the gene for the CD8+T cells protein CXCR6, the mice developed worse Alzheimers disease-related symptoms. This effect was partially because the CD8+T cells without CXCR6 failed to accumulate in the brain near the microglia or plaque site. These cells also did not acquire the appropriate suppressive function. Thus, disrupting the CD8+T cells ability to perform the handshake prevented its protective effect against Alzheimers disease symptoms. We have two major findings, Chi said. One is the crucial role of CD8+T cells in maintaining homeostasis of the brain, thereby providing a protective role in Alzheimers disease. Homeostasis is the process of keeping a system in a relatively stable state. In this case, the CD8+T cells attempt to limit the disruption caused by microglia dysfunction and Alzheimers disease-related plaques. The other major finding is identifying the central importance of the T cell protein CXCR6 for CD8+T-cell accumulation and function in the brain, Chi continued. We really need to characterize these kinds of neuro-immune interactions better. Only by understanding this basic biology can we advance the field and find new treatments. (ANI)
|
